Applied DNA COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vac...
March 18 2020 - 3:04PM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA”) today
announced that its COVID-19 collaboration partner, Takis Biotech, a
Rome, Italy-based a company focused on the development of cancer
vaccines founded by scientists from Merck Research Laboratories,
has received approval from the Italy’s Ministry of Health to begin
a pre-clinical trial of a COVID-19 vaccine candidate. As announced
by Applied DNA on March 2, 2020, the vaccine is one of four
PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine
candidates under joint development by Takis Biotech and Applied
DNA. Applied DNA entered large-scale production of the candidates
in March 2020. Takis Biotech anticipates first results of its
pre-clinical trial will be available in April 2020.
Click here to read Takis Biotech’s announcement (in English and
Italian):
http://www.takisbiotech.it/index.php/en/news/209-rome-17-march-2020-takis-a-biotech-company-in-castel-romano-rome-announces-that-it-is-ready-to-test-its-covid-19-vaccine-on-pre-clinical-models
Click here to learn more about Applied DNA’s proprietary linear
DNA production capabilities for DNA vaccines:
https://www.wshu.org/post/covid-19-brings-dna-vaccines-forefront
About Takis Biotech
Takis is a Biotech Company created by a group of scientists from
Merck Research Laboratories (MRL). The group has more than 15 years
of experience and an established track record in drug discovery in
Oncology and is recognized for the conception and implementation of
a number of innovative technologies. One of the main assets of
Takis is the expertise in in vivo electro-gene-transfer, which can
be used for a variety of clinically useful applications, from
vaccine development to somatic gene therapy. Takis pipeline include
four Cancer Vaccine candidates based on this technology. Takis is
also actively involved in the generation of humanized monoclonal
antibodies for use in Oncology and Infectious Diseases.
Visit www.takisbiotech.it for more information.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, diagnostics and pre-clinical
nucleic acid-based therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN.
Web: www.adnas.com | twitter: @APDN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200318005699/en/
Investor contact: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com
Program contact: Brian Viscount, Applied DNA, 631-240-8877,
brian.viscount@adnas.com
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024